Recursion Pharmaceuticals is a clinical-stage biotechnology company developing drugs to treat rare monogenic diseases. It was founded in 2013 and is based in Salt Lake City, Utah.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Recursion Pharmaceuticals news
23.03.2022
Recursion Pharmaceuticals' GAAP loss for 2021 was $186.479 million, up 2.1 times from $87.006 million in the previous year. Revenue increased 2.6 times to $10.178 million from $3.962 million a year earlier.
Source: ir.recursion.com
10.11.2021
Recursion Pharmaceuticals' GAAP loss for 9M 2021 was $121.546 million, up 98.5% from $61.24 million in the previous year. Revenue increased six-fold to $7.645 million from $1.271 million a year earlier.
Source: ir.recursion.com
29.09.2021
Recursion has received orphan drug status from the FDA for its small molecule allosteric inhibitor MEK1 and MEK2, REC-4881. The drug is a potential drug for familial adenomatous polyposis. The company expects within 9 months to start enrolling participants for a Phase II clinical trial.
Source: ir.recursion.com
13.08.2021
Recursion Pharmaceuticals' GAAP loss for 6M 2021 was $74.118 million, up 98.4% from $37.367 million in the previous year. Revenue increased 20.8 times to $5.111 million from $0.246 million a year earlier.
Source: ir.recursion.com
General information
| Company name | Recursion Pharmaceuticals |
|---|---|
| Tags | #pharmacy, #biotechnology, #genome |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 41 South Rio Grande Street Salt Lake City, UT 84101 United States |
| Mailing address | 41 South Rio Grande Street Salt Lake City, UT 84101 United States |
| Website | ir.recursion.com |
| Information disclosure | www.sec.gov |
English (US) 